News & Updates

More evidence suggests that people exposed to more air pollution during the pandemic are at greater risk for COVID-19 infection, hospitalization, and death, but the exact mechanism behind the link is unknown.

In the PRO analyses of the phase III CodeBreak 200 trial, the first-in-class KRAS^G12C inhibitor sotorasib improved quality of life (QoL) of patients with pretreated KRAS^G12C-mutated advanced non-small-cell lung cancer (NSCLC) compared with docetaxel.

In a national cohort study in Singapore, a booster dose of BNT162b2 maintained individual protection against severe COVID-19 disease among adolescents aged 12–17 years.

In individuals with resectable non-small-cell lung cancer (NSCLC), the addition of perioperative durvalumab to neoadjuvant chemotherapy improved pathologic complete response (pCR) and event-free survival (EFS), findings from the AEGEAN study have shown.